JWM
RPRX icon

Janiczek Wealth Management’s Royalty Pharma RPRX Stock Holding History

Janiczek Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$238 Hold
9
– – ﹤0.01% 1036
2024
Q1 		$274 Hold
9
– – ﹤0.01% 1036
2023
Q4 		$253 Buy
+9
New +$247 ﹤0.01% 1042

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janiczek Wealth Management's RPRX Position: Q2 2024 in Review

Janiczek Wealth Management held its Royalty Pharma (RPRX) position steady in Q2 2024 at 9 shares worth $238. The position accounts for ﹤0.01% of the portfolio, ranked #1036.

Janiczek Wealth Management first reported a position in RPRX in Q4 2023 and has held it in 3 quarters since. The position peaked at $274 in Q1 2024. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

  • Janiczek Wealth Management held 9 shares of Royalty Pharma worth $238 as of Q2 2024.
  • Janiczek Wealth Management left its Royalty Pharma share count unchanged in Q2 2024.
  • Royalty Pharma made up ﹤0.01% of Janiczek Wealth Management's portfolio in Q2 2024, its #1036 holding.
  • Janiczek Wealth Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 3 quarters since.
  • Janiczek Wealth Management's Royalty Pharma position peaked at $274 in Q1 2024.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.